Search This Blog

Monday, August 10, 2026

Silence Therapeutics' divesiran meets Phase 2 endpoints in polycythemia vera, Phase 3 planned for 1H27

 

Silence Therapeutics' divesiran meets Phase 2 endpoints in polycythemia vera and Phase 3 trial planned for 1H 2027

  • Phase 2 SANRECO trial demonstrated strong efficacy for divesiran in polycythemia vera patients
  • Divesiran showed a favorable safety profile in the Phase 2 SANRECO polycythemia vera study
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)